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Abstract. Objective: Mixed results have been reported of matrix metalloproteinases (MMP) and their association with restenosis
after percutaneous coronary intervention (PCI). The current study examines whether multiple single nucleotide polymorphisms
(SNPs), covering the full genomic region of MMP2 and MMP3, were associated with restenosis in the GENDER study population.
Methods and results: The GENetic DEterminants of Restenosis (GENDER) study enrolled 3104 consecutive patients after
successful PCI. The primary endpoint was clinical restenosis, defined as target vessel revascularization (TVR), occurring in 9.8%
of the patients. From the Hapmap database, 19 polymorphisms of MMP2 and 11 of MMP3 were selected. Furthermore, in a
subpopulation, a genome-wide association analysis (GWA) was performed. No significant association was found with any of the
investigated SNPs, including the previously reported 5A/6A polymorphism (rs3025058), with regard to TVR using single SNP
analysis or haplotype analysis.
Conclusion: We found no significant association of MMP2 or MMP3 with TVR with this SNP-broad gene approach. Although
we did not test all the known polymorphisms of these genes, using tagging analyses we examined those SNPs covering all known
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haplotypes of MMP2 and MMP3 to conclude that these genes do not correlate with a genetic risk of coronary restenosis after
successful PCI.
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1. Introduction
Matrix metalloproteinases (MMPs) form a family
of over 20 zinc-dependent enzymes with proteolytic
activity against a variety of extracellular matrix com-
ponents including collagen, proteoglycans and elastin.
All MMPs have distinct although overlapping substrate
specificities [19]. Increased expression and activity
of MMPs have been identified in various pathological
processes, such as general inflammation, tumor metas-
tasis, respiratory diseases, myocardial injury, vascu-
lar aneurysms, and vascular remodeling [29]. Vascu-
lar remodeling and inflammation are important features
of restenosis after percutaneous coronary intervention
(PCI) and several, mostly small, studies found associa-
tions of MMP plasma levels or genetic polymorphisms
with restenosis [5,9,12].
MMP2 (gelatinase A) is produced by vascular
smooth muscle cells (VSMCs) to degrade basement
membrane components and other matrix proteins dur-
ing migration and proliferation of these cells. Different
animal models for restenosis showed upregulation of
MMP2 during intima formation [13,17]. Furthermore,
MMP2 plasma levels were found to be increased after
PCI and associated with restenosis [7,9,16]. Although
genetic polymorphisms in the MMP2 gene have been
associated with myocardial infarction (MI) [8,26] and
heart failure [11,25], there are no studies published de-
scribing their association with coronary restenosis.
MMP3 (stromelysin-1) cleaves a wide variety of ma-
trix proteins and is considered to reduce the matrix con-
tent of the vascular wall. Higher MMP3 expression
is associated with the development of atherosclerotic
plaques with less matrix protein and as a result small-
er and more prone to rupture plaques (i.e. lipid rich
plaques). On the other hand, low MMP3 expression
genotypes are predisposed to develop relatively larg-
er and more stable plaques (i.e. fibrotic plaques) [29].
However, in a MMP3 knockout mouse model, Johnson
et al. found that in absence of MMP3 the plaques where
not only larger but that they also had a lower smooth
muscle cell content, making them less stable [14]. Part
of their explanation was that MMP3 has a broad sub-
strate specific, including activation of other MMPs and
that therefore many mechanisms could account for the
effects of MMP3 [14]. Functional studies have shown
that the MMP3 -1612 5A/6A promoter polymorphism
(rs3025058) is associated with decreased MMP3 ex-
pression levels [3,18,28]. In addition, several stud-
ies describe the association of this polymorphism with
restenosis. For example, de Maat et al. found an as-
sociation between the 6A6A MMP3 genotype and an
increased risk of restenosis after balloon angioplas-
ty [5]. The same conclusion was made by Humphries
et al. [12]; however other studies could not identify this
association [4,10].
MMPs have been extensively studied on their associ-
ation with different cardiovascular endpoints. The re-
sults with regard to restenosis have been mixed. To clar-
ify these uncertainties we conducted this study in the
large prospective GENetic DEterminants of Resteno-
sis (GENDER) study population. With this study we
systematically examined whether multiple single nu-
cleotide polymorphisms (SNPs), covering the full ge-
nomic region of MMP2 and MMP3, were associated




The present study population has been described pre-
viously [1]. In brief, the GENDER project was de-
signed to study the association between various gene
polymorphisms and clinical restenosis. All included
patients were treated successfully for stable angina,
non-ST-elevation acute coronary syndromes or silent
ischemia by PCI in four out of the eight academic med-
ical centers in the Netherlands. Patients treated for
acute ST elevation myocardial infarction were exclud-
ed. Also excluded from analysis were patients suffer-
ing from events occurring within one month after the
procedure, since these events were mostly attributable
to sub-acute stent thrombosis or occluding dissections,
and not to restenosis. During the study, no drug-eluting
stents were used. Follow-up lasted for at least nine
months, except when a coronary event occurred. Clini-
cal restenosis, defined as renewed symptoms requiring
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Table 1
Demographic, clinical and lesion characteristics of the total GENDER population
composed of 3,104 patients
Cases (n = 304) Controls (n = 2,800) p-value
Age (years) 61.7 ± 10.1 62.2 ± 10.8 0.46
BMI (kg.m−2) 26.9± 3.7 27.0 ± 3.9 0.70
Male sex 220 (72.4%) 1996 (71.3%) 0.69
Caucasian ancestry 295 (97.0%) 2714 (96.9%) 0.92
Diabetes 63 (20.7%) 390 (13.9%) 0.001
Hypercholesterolemia 188 (61.8%) 1702 (60.8%) 0.72
Hypertension 138 (45.4%) 1121 (40.0%) 0.07
Current smoker 62 (20.4%) 700 (25.0%) 0.08
Family history of MI 121 (39.8%) 977 (34.9%) 0.09
Previous MI 109 (35.9%) 1130 (40.4%) 0.13
Previous PCI 64 (21.1%) 493 (17.6%) 0.14
Previous CABG 36 (11.8%) 340 (12.1%) 0.88
Stable angina 198 (65.1%) 1881 (67.2%) 0.47
Acute coronary syndrome 106 (34.9%) 974 (31.2%) 0.19
Multivessel disease 148 (48.7%) 1284 (45.9%) 0.35
Peripheral vessel disease 12 (3.9%) 92 (3.3%) 0.54
Lipid lowering medication 171 (56.3%) 1516 (54.1%) 0.48
Restenotic lesions 27 (8.9%) 181 (6.5%) 0.11
Total occlusions 56 (18.4%) 372 (13.3%) 0.01
Type C lesion 94 (30.9%) 708 (25.3%) 0.03
Proximal LAD 70 (23.0%) 619 (22.1%) 0.71
RCX 75 (24.7%) 764 (27.3%) 0.33
Stenting 207 (68.1%) 2145 (76.6%) 0.001
Number of stents 0.98 ± 0.05 1.01 ± 0.01 0.58
Values were given as n (%) or mean ± SD;
BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass graft; LAD, left anterior descending
branch of the left coronary artery; RCX, circumflex branch of the left coronary
artery.
p-value determined by Pearsons Chi-Square (discrete variables) or unpaired 2-
sided t-test (continuous variables).
target vessel revascularization (TVR), either by repeat-
ed PCI or CABG, was designated to be the primary
endpoint. The study protocol met the criteria of the
Declaration of Helsinki and was approved by the Medi-
cal Ethics Committees of each participating institution.
Written informed consent was obtained from all partic-
ipating patients in advance of the PCI procedure. Blood
was collected in EDTA tubes at baseline and genomic
DNA was extracted following standard procedures.
2.2. Candidate gene approach
SNPs of MMP2 and MMP3 were selected from
the HapMap database (http://www.hapmap.org). Us-
ing the data from the CEU population, tagging SNPs,
with a minor allele frequency > 5%, were selected
to cover each haplotype block within the genes (using
Haploview program, version 4.1 [2]). Five SNPs in
MMP2 were analyzed (rs243866, rs857403, rs243849,
rs2287076 and rs10775332) and 2 SNPs in MMP3
(rs679620 and rs646910). Furthermore, the 5A6A
promoter polymorphism of MMP3 (rs3025058) was
added to the tagging SNPs. All SNPs were genotyped
by matrix-assisted laser desorption/ionisation time-of-
flight (MALDI-TOF) mass spectrometry (MS), us-
ing the Sequenom MassARRAYtm methodology (Se-
quenom Inc, San Diego, CA, USA), following manu-
facturer’s instructions. As quality controls, 368 (11%)
of the samples were genotyped in duplo. No inconsis-
tencies were observed. All the blanks (5%) were neg-
ative. Cluster plots were made of the signals from the
low and the high mass allele. Independent researchers
carried out scoring. Disagreements or vaguely posi-
tioned dots (< 1%) produced by Typer 4.0 (Sequenom
Inc.) were left out of the results.
2.3. Genome wide association study
A genome wide association study was performed in
a selection of cases and controls from the GENDER
study and has been described previously [20]. In brief,
cases and controls were selected from the total GEN-
DER study population and matched by age, gender and
other clinical factors such as diabetes and current smok-
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Table 2
Single nucleotide polymorphisms of MMP2 and the association with target vessel revascularization
SNP Major allele Minor allele MAF Approach Rel. position Gene region HR 95% CI p-value
rs893226 G T 0.40 GWAS −10496 1,00 (0.840 1,20) 0,97
rs1005913 A C 0.29 GWAS −8871 Promoter 0.99 (0.82–1.20) 0.95
rs1347653 G T 0.17 GWAS −8352 Promoter 0.92 (0.72–1.17) 0.42
rs16955194 G A 0.06 GWAS −8064 Promoter 1.38 (0.90–2.11) 0.14
rs243866 G A 0.24 Candid. −1855 Promoter 0.90 (0.74–1.09) 0.28
rs857403 A T 0.18 Candid. 3316 Intron 0.83 (0.67–1.04) 0.11
rs17301608 C T 0.39 GWAS 5219 Intron 1.09 (0.92–1.29) 0.32
rs1053605 C T 0.08 GWAS 6216 Coding exon 1.15 (0.84–1.57) 0.40
rs9302671 G T 0.37 GWAS 8334 Intron 1.09 (0.92–1.30) 0.32
rs243849 C T 0.17 Candid. 10313 Coding exon 0.82 (0.65–1.04) 0.11
rs243842 T C 0.34 GWAS 14031 Intron 0.96 (0.80 1.15) 0.63
rs183112 G A 0.15 GWAS 14291 Intron 1.24 (0.97–1.58) 0.09
rs1992116 C T 0.46 GWAS 14500 Intron 1.16 (0.98–1.37) 0.09
rs243840 A G 0.20 GWAS 14768 Intron 0.83 (0.65–1.04) 0.10
rs2287076 T C 0.47 Candid. 19066 Intron 1.17 (0.99–1.38) 0.08
rs243834 A G 0.47 GWAS 23296 Intron 0.88 (0.74–1.04) 0.14
rs10775332 C T 0.46 Candid. 23335 Coding exon 1.10 (0.93–1.30) 0.22
rs1861320 G T 0.47 GWAS 27649 Downstream 1.12 (0.94–1.33) 0.19
rs8054459 A G 0.44 GWAS 31158 Downstream 0.84 (0.71–1.01) 0.06
SNP, single nucleotide polymorphism; MAF, minor allele frequency; Rel., relative; HR, hazard ratio; CI, confidence interval;
candid., candidate approach; GWAS, genome wide association scan.
Cox regression analysis with additive model with correction for sex, age and ethnicity in the GWAS SNPs and also correction
for diabetes, total occlusion, stenting and type C lesions in the candidate SNPs.
Table 3
Single nucleotide polymorphisms of MMP3 and the association with target vessel revascularization
SNP Major allele Minor allele MAF Approach Rel. position Gene region HR 95% CI p-value
rs645419 A G 0.48 GWAS −2045 Promoter 1.04 (0.87–1.25) 0.66
rs3025058 5A 6A 0.50 Candid. −1676 Promoter 1.09 (0.92–1.28) 0.33
rs522616 A G 0.21 GWAS −772 Promoter 1.03 (0.83–1.27) 0.80
rs679620 A G 0.50 Candid. 657 Coding exon 1.07 (0.90–1.26) 0.46
rs3025066 A G 0.06 GWAS 3794 Intron 1.09 (0.78–1.54) 0.61
rs566125 C T 0.15 GWAS 3806 Intron 0.89 (0.69–1.15) 0.38
rs646910 T A 0.13 Candid. 4755 Intron 1.06 (0.83–1.35) 0.67
rs595840 T C 0.48 GWAS 9380 Downstream 1.03 (0.86–1.24) 0.72
rs527832 C T 0.12 GWAS 12393 Downstream 0.94 (0.72–1.23) 0.67
rs1010698 A C 0.48 GWAS 13256 Downstream 1.03 (0.86–1.24) 0.72
rs1034375 A C 0.07 GWAS 18805 Downstream 1.23 (0.90–1.67) 0.19
SNP, single nucleotide polymorphism; MAF, minor allele frequency; Rel., relative; HR, hazard ratio; CI, confidence interval;
candid., candidate approach; GWAS, genome wide association scan.
Cox regression analysis with additive model with correction for sex, age and ethnicity in the GWAS SNPs and also correction
for diabetes, total occlusion, stenting and type C lesions in the candidate SNPs.
ing that have been previously associated to restenosis.
A genome-wide association analysis was conducted us-
ing the Illumina Human 610-Quad Beadchips following
manufacturer’s instructions. These beadchips contain
620,901 single nucleotide polymorphism (SNP) and
copy number variants (CNV) probes, covering 89% of
the common genetic variation in the European popula-
tion at r2 > 0.8. After genotyping, samples and genetic
markers were subjected to a stringent quality control
protocol. Of the initially selected patients (321 cases
and 620 controls), 295 cases and 571 controls fulfilled
all criteria. The SNPs captured in the MMP2 region
between positions 54060397 and 54102050 on chro-
mosome 16 and the SNPs in the MMP3 region between
positions 102206231 and 102225888 on chromosome
11 were selected for further analyses (see Tables 2 and
3 for rs numbers).
2.4. Statistical analysis
Of the baseline characteristics the discrete variables
are expressed as counts or percentages and were com-
pared with chi-square tests. Continuous variables are
expressed as mean (± standard deviation) and were
compared by means with unpaired 2-sided t-test. As-
sociations of the genotypes of the individual SNPs with
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Fig. 1. Linkage disequilibrium structure of 19 MMP2 SNPs on chromosome 16. Values shown in D’, ∗SNP from GWAS, + SNP from candidate
approach.
TVR were calculated assuming an additive model us-
ing a Cox proportional hazards model. We controlled
for age, sex and ethnicity in the Cox-regression by in-
cluding them as covariates. Furthermore, based on the
baseline characteristics, we also corrected for diabetes,
stenting, total occlusion and type C lesions in the anal-
ysis of the candidate approach SNPs. These additional
corrections were not necessary for the GWAS SNPs,
since that subpopulation was matched for known risk
factors as described above. Recessive and dominant
models were also tested. After Bonferroni correction
for multiple testing, we considered a statistically sig-
nificant association (at p < 0.05) for any SNP with
p-value < 0.0017.
The program Haploview was used to estimate allele
frequencies, test the consistency of the genotype fre-
quencies at each SNP locus with Hardy-Weinberg equi-
librium, and estimate and plot pairwise linkage dise-
quilibrium (LD) measurements between SNPs.
Haplotypes and haplotype frequencies were calcu-
lated using PHASE software (http://www.stat.washing
ton.edu/stephens/) [22–24]. Haplotypes with a fre-
quency of less than 5% were combined and included
in all analyses, without reporting the results. The hap-
lotype analysis approach performed in this study as-
sumes an additive effect of the haplotypes, and details
of this approach have been described elsewhere [27].
Haplotype analyses were performed using STATA for
haplotypes with a frequency > 5%. Their effects were
calculated using a Cox proportional hazards model in-
cluding sex, age, and ethnicity and weighted for the
probability of having the haplotype.
A p-value < 0.05 was considered statistically signif-




A total of 3,146 patients had a complete follow-up
(99.3%) with a median duration of 9.6 months (in-
terquartile range 3.9). Out of 3,146 patients 42 had an
event in the first 30 days. These patients were excluded
from further analysis, according to the protocol. Base-
line characteristics of the population are shown in Ta-
ble 1. Of the 3,104 patients, 304 (9.8%) patients under-
went TVR during follow-up. 51 patients died (1.6%)
and 22 (0.7%) suffered from MI. In the total GENDER
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Fig. 2. Linkage disequilibrium structure of 11 MMP3 SNPs on chromosome 11. Values shown in D’, ∗SNP from GWAS, + SNP from candidate
approach.
population use of lipid lowering medication was equal
in both cases and controls. Diabetes, total occlusion
and C-type lesion were significantly more frequent in
the cases (p-value = 0.001, 0.01 and 0.03 respectively),
whereas the percentage of patients receiving a coro-
nary stent was significantly higher in the control group
(p-value = 0.001).
3.2. Genotypic analyses
The SNPs included in this study are listed in Tables 2
and 3 for MMP2 and MMP3,respectively. The 19 poly-
morphisms of MMP2 and 11 polymorphisms of MMP3
provided coverage of all haplotype blocks (Figs 1 and
2, respectively) and were all in Hardy-Weinberg equi-
librium (p-value > 0.05). Associations with TVR as
a marker of restenosis were calculated assuming an
additive model. No significant associations were ob-
served between any of the MMP2 and MMP3 poly-
morphisms, including the previously reported 5A/6A
polymorphism (rs3025058), and TVR. Dominant and
recessive models did not alter these effects (data not
shown).
After analyzing the subpopulations of patients with
(n = 2352) or without (n = 752) receiving coronary
stents during PCI, similar results were obtained. None
of the SNPs was associated with TVR in neither of the
subpopulations.
Linkage disequilibrium structure is shown in Fig. 1
and in Fig. 2. MMP2 included 4 haplotype blocks,
whereas MMP3 had only 1. The haplotypes of the
different blocks of MMP2 were calculated as shown
in Table 4. The most frequent haplotype was used as
reference. None of the haplotypes was significantly
associated with the outcome parameter TVR. In line
with the single SNP analysis, haplotype analysis of
MMP3 also did not show any significant association
with TVR (Table 5).
4. Discussion
Polymorphisms of MMPs have been associated
with different cardiovascular events [5,11,15,21,26,
29]. Studies of their association with restenosis after
PCI are however scarce. Most of these studies look
into the relation of the 5A6A promoter polymorphism
of MMP3 and restenosis, however those results are
mixed [4,5,10,12]. The main finding of the present
study is that after testing several polymorphisms in
MMP2 and MMP3 using a candidate gene approach we
did not find any significant association with coronary
J.J.W. Verschuren et al. / Matrix metalloproteinases 2 and 3 gene polymorphisms and the risk of target vessel revascularization 271
Table 4
Haplotype analysis of MMP2
Haplotype Frequency HR 95% CI p-value
Block 1 AG* 54.56%
CG 28.12% 1.00 (0.85–1.17) 0.99
AT 17.28% 0.91 (0.75–1.11) 0.37
Block 2 AA 57.67%
GA∗ 23.89% 0.87 (0.72–1.05) 0.15
AT 18.05% 0.82 (0.66–1.02) 0.08
Block 3 CTCTATAC 35.77%
CGCCACAT 35.42% 0.88 (0.73–1.06) 0.18
CGTTGCGT 15.43% 0.90 (0.72–1.12) 0.35
TGCTATAC 7.11% 1.08 (0.81–1.44) 0.61
Block 4 TTA 45.60%
CGG 44.40% 0.89 (0.76–1.05) 0.16
CGA∗ 9.47% 1.10 (0.86–1.42) 0.44
∗wild type; HR, hazard ratio; CI, confidence interval.
Table 5
Haplotype analysis of MMP3
Haplotype Frequency HR 95% CI p-value
AACTTCAAAAA∗ 42.43%
ACTCTCAGGCG 12.84% 1.157 (0.84–1.59) 0.37
ACCCATAGACG 11.99% 0.994 (0.80–1.24) 0.95
ACCCTCAGGCG 9.35% 1.112 (0.87 – 1.42) 0.40
CCCCTCAGACG 7.71% 1.212 (0.93 – 1.58) 0.16
ACCCTCAGACG 5.72% 1.059 (0.78–1.44) 0.72
AACTTCGAAAA 5.59% 1.105 (0.87–1.41) 0.42
∗wild type; HR, hazard ratio; CI, confidence interval.
restenosis. Since in the meantime a GWAS was car-
ried out in a subpopulation of the GENDER study [20],
we decided to include the genotyped polymorphisms
in the genomic regions of both MMP2 and MMP3 in
our analyses. None of the SNPs was associated with
restenosis. Combining both approaches strengthened
our findings of the lack of association between the two
MMP genes and coronary restenosis after successful
PCI.
Previously, Hojo et al. reported a significant associa-
tion of increased serum level of MMP2 four hours after
PCI and the occurrence of restenosis [9]. Their study
population was however very small and the patient
characteristics of the 29 patients with follow-up were
not well described. Recently, Katsaros et al. reported
that in a population of 85 patients with stable angina
pectoris receiving DES, increased MMP2 serum activ-
ity was associated with dramatically increased resteno-
sis rates [16]. Although these results look promising
for possible identification of patients prone to develop
restenosis, larger studies are needed to replicate these
results. In our, much larger patient population, we
could not confirm their results with genotypic data.
The increased risk of restenosis with the 6A6A
MMP3 genotype was described by de Maat et al. and
Humphries et al. in patients after balloon angioplas-
ty without stenting [5,12]. The latter study also ana-
lyzed a subpopulation of patients who received an in-
tracoronary stent and they could not identify an associ-
ation with the 6A6A MMP3 genotype and restenosis.
This difference probably indicates that different pro-
cesses are involved in these two patient groups. Howev-
er, since balloon angioplasty without stenting becomes
more rare, the clinical relevance of this finding is de-
creasing. In the GENDER no significant association
with TVR of any of the SNPs was detected in neither
of the subpopulations. Moreover, the 5A6A polymor-
phism was also not related to restenosis, not in the total
population nor in one of the subgroups.
In the GENDER study all patients that were stented
received one or more bare-metal stents (BMS). It could
be argued that a possible role of investigated MMPs
might be ascribed in restenosis in a patient group receiv-
ing drug-eluting stents (DES). This is however highly
unlikely since DES are associated with a reduction in
the development of restenosis, which would more like-
ly diminish a possible genotype-dependent difference
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in neointima formation. Definite data on this topic is
however lacking.
A limitation of our study is that the patients included
in the GENDER study were mostly patients with a
Caucasian ancestry (96.9%). Different results may be
obtained in other ethnic groups. Furthermore, we did
not test all known polymorphisms in the two genes
of interest, but since SNPs were selected taking into
account the LD measurements, all haplotype blocks
were covered. Moreover, no significant associations
were obtained by means of haplotype analysis. We
therefore think it is valid to conclude that no major
effects are to be expected from these genes. Also, our
findings are based on one single study. However, since
the GENDER study is a large prospective follow-up
study and taken in account that the previous reports
are heterogeneous and in smaller patients groups, the
power of these results is large enough to draw these
conclusions.
In conclusion, with this study we provide evidence
that, with regard to restenosis, a solid association with
genetic variation of MMP2 and MMP3 is absent. Al-
though we did not test all the known polymorphisms of
the MMP2 and MMP3 genes, using tagging analyses
we examined those SNPs covering all known haplo-
types of MMP2 and MMP3 to conclude that genetic
variation of these genes does not correlate with a ge-
netic risk of coronary restenosis after successful PCI.
As the search for genetic factors involved in the pro-
cess of restenosis continues, we merely exclude genetic
variation in two previously proposed candidate genes
for involvement in the increased risk for restenosis, so
future research may focus on other targets.
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